Company Performance - Siga Technologies Inc. closed at $6.35, with a daily increase of +0.32%, underperforming the S&P 500's gain of 1.83% [1] - Over the past month, Siga's shares appreciated by 3.94%, outperforming the Medical sector's decline of 3.48% and the S&P 500's decline of 3.31% [1] Analyst Estimates - Analysts and investors are closely monitoring Siga Technologies Inc. ahead of its upcoming earnings disclosure, with a focus on any changes in analyst estimates [2] - Upward revisions in estimates indicate analysts' positive outlook on the company's business operations and profit generation capabilities [2] Zacks Rank and Valuation - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Siga Technologies Inc. at 3 (Hold) [4] - Siga Technologies Inc. has a Forward P/E ratio of 5.06, which is a discount compared to the industry's average Forward P/E of 17.59 [5] - The Medical - Drugs industry, to which Siga belongs, has a Zacks Industry Rank of 70, placing it in the top 28% of over 250 industries [5]

Group 1 - Siga Technologies Inc. (SIGA) is a notable stock in the Medical sector, currently outperforming the sector with a year-to-date return of approximately 15.5% compared to the sector average of 0.3% [4] - The Zacks Rank for Siga Technologies Inc. is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings outlooks [3] - The Zacks Consensus Estimate for SIGA's full-year earnings has increased by 3% over the past quarter, reflecting stronger analyst sentiment [4] Group 2 - Siga Technologies Inc. is part of the Medical - Drugs industry, which consists of 172 companies and is currently ranked 71 in the Zacks Industry Rank; this industry has seen an average loss of 4% year-to-date [6] - Another stock in the Medical sector, AnaptysBio, Inc. (ANAB), has a year-to-date return of 7.8% and a Zacks Rank of 2 (Buy), with its consensus EPS estimate increasing by 11.9% over the past three months [5][6] - The Medical - Biomedical and Genetics industry, to which AnaptysBio belongs, has a current ranking of 63 and has experienced a year-to-date decline of 6.6% [6]

Group 1 - The article discusses the author's extensive background in life sciences, specifically in the research and development of novel Cell & Gene Therapies (CGT) for various clinical needs, including orthopaedics and rare diseases [1] - The author emphasizes the importance of utilizing their expertise to assess the potential of novel treatments and their capacity to drive shareholder returns [1] - The focus of the analysis will be on biotechnology, pharmaceutical, Medtech, and healthcare stocks, providing insights into the companies within these sectors [1]

I’m a stock analyst with an MBA and a background in healthcare, bringing years of experience as a Registered Nurse dedicated to patient care. I've had the privilege of sharing my insights on Seeking Alpha since 2017. I am most interested in identifying underlying assumptions in stock valuations by emphasizing financial modeling techniques like DCF analysis. I then provide scenario-based forecasts to help readers gauge reasonable outcomes. I am influenced by books like Superforecasting and Antifragile. As su ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2024 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) (Stat ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Invest ...

The latest trading session saw Siga Technologies Inc. (SIGA) ending at $7.08, denoting a -0.42% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a loss of 0.33% for the day. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq lost 0.56%.The company's shares have seen an increase of 2.01% over the last month, surpassing the Medical sector's loss of 4.31% and the S&P 500's gain of 1.83%.Analysts and investors alike will be keeping a close eye on the perfo ...

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. Under the agreement, SIGA has exercised its option to license the ...

Siga Technologies Inc. (SIGA) closed the most recent trading day at $6.80, moving +0.89% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.47%. Meanwhile, the Dow gained 0.79%, and the Nasdaq, a tech-heavy index, added 0.28%. The company's shares have seen a decrease of 14.47% over the last month, not keeping up with the Medical sector's loss of 4.27% and the S&P 500's gain of 3.48%. The upcoming earnings release of Siga Technologies Inc. will be of great interest to invest ...